A detailed history of Farther Finance Advisors, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 23 shares of KRYS stock, worth $3,663. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23
Previous 19 21.05%
Holding current value
$3,663
Previous $3.46 Million 20.91%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

BUY
$174.7 - $213.66 $698 - $854
4 Added 21.05%
23 $4.19 Million
Q1 2024

May 13, 2024

BUY
$108.01 - $179.35 $1,728 - $2,869
16 Added 533.33%
19 $3.35 Million
Q4 2023

Feb 14, 2024

BUY
$96.0 - $128.29 $1,536 - $2,052
16 Added 533.33%
19 $2.36 Million
Q2 2023

May 13, 2024

SELL
$78.48 - $130.32 $1,255 - $2,085
-16 Reduced 84.21%
3 $352,000
Q2 2023

Sep 12, 2023

BUY
$78.48 - $130.32 $235 - $390
3 New
3 $352,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.09B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.